All In Biotech

Drug Trial Radar · NCT05858736

Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors

Safety, Pharmacokinetics (PK) and Efficacy of AI-061, A 1:1 Co-formulation of AI-025 (Anti-PD-1) and ONC-392 (Anti-CTLA-4) Antibodies in Advanced Solid Tumors: An Open-Label Phase 1 Study

Last checked: Nov 19, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

18

Actual

Start

Jul 11, 2023

Primary completion

Jul 31, 2026

Study completion Jul 31, 2026

Sponsor

Lead sponsor
OncoC4, Inc.Industry
Sponsor type
Industry
Collaborators
OncoC4 AU Pty Ltd; Avance Clinical Pty Ltd.
First posted
May 15, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

AI-061 is a co-formulation drug product (DP) consisting of 1:1 ratio mix of AI-025, an anti-PD-1 antibody, and ONC-392, an anti-CTLA-4 antibody. This is a dose escalation study to identify the maximum toxicity dose (MTD) or the recommended phase 2 dose (RP2D).

Conditions

  • Melanoma
  • Non Small Cell Lung Cancer
  • Head and Neck Squamous Cell Carcinoma
  • High Grade Serous Adenocarcinoma of Ovary
  • Primary Peritoneal Carcinoma
  • Fallopian Tube Cancer
  • Endometrial Cancer
  • Cervical Cancer
  • Renal Cell Carcinoma
  • Bladder Cancer
  • Esophageal Cancer
  • Gastric Cancer
  • Gastroesophageal-junction Cancer
  • Colorectal Cancer
  • Anal Cancer
  • Hepatocellular Carcinoma
  • Bile Duct Cancer

Interventions

  • AI-061Drug

    A 1:1 Co-formulation of AI-025 (Anti-PD-1) and ONC- 392 (Anti-CTLA-4) Antibodies.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Limiting Toxicity (DLT)Time frame: 21 days after first treatment
  2. Maximum Toxicity Dose (MTD)Time frame: 21 day after first treatment
  3. Recommended Phase II Dose (RP2D)Time frame: 21 days after first treatment
  4. Incidence of treatment emergent adverse events (TEAE)Time frame: From the day with first treatment to 90 days after the last treatment.

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • St. Vincent's Private Hospital

    Darlinghurst, New South Wales, Australia

  • Mater Misericordiae Ltd.

    Brisbane, Queensland, Australia

  • Tasman Oncology Research

    Southport, Queensland, Australia

  • Cancer Research SA

    Adelaide, South Australia, Australia

  • Southern Oncology Clinical Research Unit

    Bedford Park, South Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.